Cardiomyocytes are the major cell type in the heart. Unlike other normal cell types or tumor cells, cardiomyocytes cease to replicate after birth in most mammal species. During cardiac injury, cardiomyocytes can develop hypertrophy to compensate for the loss of cells by necrosis or apoptosis. Enlargement of cardiomyocytes are often observed with various forms of heart disease and have been shown to contribute to heart failure (1) (2) (3) (4) (5) . In parallel with cardiomyocyte hypertrophy, measurements of oxidative biomarkers have demonstrated an association between oxidative stress and heart failure (6, 7) . An increase in lipid peroxidation products has been found in heart failure patients and the level of this increase correlates with the severity of heart failure (8) . Ischemia and ischemic reperfusion are two major causes of increases in reactive oxygen species. It has been shown that ischemia impairs mitochondrial function and decreases the activity of superoxide dismutase and glutathione peroxidase, resulting in an increased amount of H 2 O 2 detectable in the ischemic region of the heart (9, 10). Unlike ischemia, ischemic reperfusion enhances oxidant generation through abnormal mitochondrial function as well as activated xanthine oxidase, which produces H 2 O 2 when converting hypoxanthine to xanthine. Cell injury in the ischemic area can cause an infiltration of neutrophils, which produce oxidants and cytokines. Certain cytokines, such as tumor necrosis factor-␣, trigger mitochondrial release of superoxide (11) . As a result of the inflammatory response, there is a further increase in oxidants in the damaged area of the heart. In addition to these traditionally known sources of reactive oxygen species, recent work have found that angiotensin II (AngII) 1 and several growth factors can also induce an increase in reactive oxygen species (12, 13) . AngII activates a plasma membrane-associated NAD(P)H oxidase to produce superoxide (13, 14) . Regardless of the abundant sources of oxidants, we have found that H 2 O 2 induces enlargement of cardiomyocytes (15) .
A number of experimental models have been developed to study the mechanism of cardiomyocyte enlargement. It is commonly known that AngII, endothelin-1, and catecholamines induce cardiomyocyte hypertrophy via binding to their receptors on the plasma membrane and initiate a cascade of signaling events, including activation of phosphoinositol 3-kinase (PI3K) and MAPKs (4, 16 -20) . These signaling molecules regulate phosphorylation and activation of specific transcription factors, leading to transcriptional activation of a unique set of genes, among which are the atrial natriuretic factor, b-type natriuretic peptide, ␤ myosin heavy chain, ventricular myosin light chain 2, and skeletal ␣-actin (2, 3, 21) .
AP-1 is a transcription factor thought to play a critical role in cardiomyocyte hypertrophy. AngII, endothelin-1, and catecholamines have been shown to transiently activate AP-1 transcription factors (22, 23) . AP-1 transcription factors consist of homodimers of Jun family members (c-Jun, v-Jun, JunB, and JunD), heterodimers of Jun and Fos (c-Fos, v-Fos, FosB, Fra1, and Fra2), or heterodimers of Jun and the Activating Transcription factor (ATF2, ATF3/LRF1, B-ATF) (24, 25) . A number of hypertrophy-associated genes, for example, atrial natriuretic factor, skeletal ␣-actin, and ventricular myosin light chain 2, contain AP-1 cis-elements in their promoters (26 -28) . Increased expression of c-Fos and phosphorylation of c-Jun or phosphorylation of ATF-2 all contribute to activation of AP-1. Increased expression of c-Fos may result from activation of Elk-1 transcription factors because of phosphorylation by MAPK family member ERKs (29) . In contrast, c-Jun and ATF-2 have been shown as a substrate for JNKs and p38, respectively (4, 22) . Compared with this well defined knowledge for activation of AP-1, the regulatory mechanism for the decay of AP-1 activity has not been well addressed.
Like endocrine hypertrophy inducers, H 2 O 2 activates PI3K, p70 S6 kinase, and three branches of MAPKs, i.e. JNKs, p38, and ERKs (30, 31) . A transient activation of AP-1 transcription factors was observed following H 2 O 2 treatment in cardiomyocytes (31) . An important component contributing to AP-1 activation by oxidants, as documented in the literature, is elevated expression of the c-fos gene (32) (33) (34) . However, little is known about the role of post-translational modification of c-Fos protein during oxidative stress in cardiomyocytes. This study investigates phosphorylation of c-Fos protein and tests the role of c-Fos phosphorylation in the stability of the protein.
EXPERIMENTAL PROCEDURES
All chemicals were purchased from Sigma unless otherwise stated. Pharmacological inhibitors were obtained from Calbiochem (La Jolla, CA).
Cardiomyocyte Isolation and H 2 O 2 Treatment-Neonatal SpragueDawley rat cardiomyocytes (1-2 days old) were isolated following the protocol previously described (15, 30) . Briefly, whole hearts were removed from 1 to 2-day-old neonates and diced into 1-2-mm pieces after removal of the atria. Heart tissue was then predigested with pancreatin solution containing 0.02% pancreatin and 0.045% collagenase for 15 min, and the supernatant was discarded to remove red blood cells. Fresh pancreatin solution was added to heart tissue in 15-min intervals until heart tissues were completely digested. Following pancreatin digestion, cells were collected by centrifugation and resuspended in Ham's F-12 medium containing 1% bovine serum albumin, 0.025% fetuin, 0.1 mM ascorbic acid, 100 units/ml penicillin G, 100 units/ml streptomycin, and 0.17% sodium bicarbonate. Fibroblasts were removed by differential plating after incubating at 37°C in 5% CO 2 for 1-2 h in Ham's F-12 medium. Unattached myocytes were then collected by centrifugation and resuspended in low glucose Dulbecco's modified Eagle's medium (DMEM) containing 1 mM sodium pyruvate, 10% fetal bovine serum (FBS, Hyclone), 100 units/ml penicillin G, and 100 units/ml streptomycin (10% FBS/DMEM). Viable cells were counted after trypan blue staining. Cells were seeded into 100-mm dishes at a density of 3 ϫ 10 6 viable cells per dish. This protocol yields over 90% myocytes as judged by sarcomeric myosin content (30) .
Following 48 h of culture in DMEM containing 10% FBS, cardiomyocytes were placed in fresh DMEM containing 0.5% FBS for a 48-h incubation. Cells were then treated with 100 M H 2 O 2 for 10 min. After H 2 O 2 treatment, media was replaced with fresh 0.5% FBS/DMEM to avoid the complication of media oxidation. Cells were incubated for 1-4 h before harvesting for various assays.
Electrophoretic Mobility Shift Assay-DNA binding assay was performed as previously described (31) . Briefly, 5 g of nuclear proteins were incubated for 30 min at 4°C in 20 l of binding buffer (12.5% glycerol, 50 mM HEPES, 2.5 mM EDTA, 5 mM dithiothreitol (DTT), and, 4 g/ml leupeptin) containing 30,000 cpm of 32 P-end labeled oligonucleotide 5Ј-CGCTTGATGAGTCAGCCGGAA-3Ј and 0.05 mg/ml poly(dIdC). In supershift experiments, 1 l of c-Fos antibody (SC number 52X, Santa Cruz Biotechnology, Santa Cruz, CA) was added to the nuclear extract in the binding buffer for a 1-h preincubation before addition of radiolabeled probes for a 30-min binding reaction at 4°C. The oligonucleotides bound to proteins were separated from free probes by electrophoresis using a 6% nondenaturing polyacrylamide gel. After electrophoresis, the gels were dried for autoradiography.
Immunoblotting-Following H 2 O 2 treatment, cells were washed twice with ice-cold phosphate buffered saline (PBS) and were harvested in 200 l of EB lysis buffer (1% Triton X-100, 10 mM Tris, pH 7.4, 5 mM EDTA, 50 mM NaCl, 50 mM NaF, and freshly added 2 mM DTT, 1 mM Na 2 VO 3 , 1 mM phenylmethylsulfonyl fluoride, 100 g/ml leupeptin, and 10 g/ml aprotinin). Protein concentrations were determined using the Bradford method according to the manufacturer's instruction (Bio-Rad). SDS-PAGE (9 or 7% acrylamide) was performed using 20 g of protein from cell lysates. Proteins were transferred overnight at 30 volts to a polyvinylidene difluoride membrane (Bio-Rad). Membranes were blocked in 5% nonfat milk for a minimum of 1 h and then incubated in the primary antibody against c-Fos (rabbit polyclonal, SC number 52X, 1:1650) or ubiquitin (mouse monoclonal, clone P4D1, 1:1000) for 2 h at room temperature or in the primary antibody against phosphothreonine (clone PTR-8, 1:200) or phosphoserine (clone PSR-45, 1:300) overnight at 4°C. These primary antibodies were obtained from Santa Cruz Biotechnology, Inc. After blotting with primary antibodies, the membranes were incubated in horseradish peroxidase-conjugated secondary antibody (Zymed Laboratories Inc., South San Francisco, CA; 1:8000) in 5% nonfat milk for 45 min. Proteins were detected with enhanced chemiluminescence (ECL) as described previously (30, 35) .
Immunoprecipitation-Immunoprecipitation was performed using 350 g of protein from cell lysates harvested as described above. Protein samples were incubated on ice or rotated at 4°C for 2 h with the primary antibody against c-Fos (1:100, rabbit polyclonal, SC number 52, Santa Cruz Biotechnology) or ubiquitin (1:100, rabbit polyclonal, SPA-200, Stressgen Biotechnologies, Victoria, Canada). Following incubation with primary antibodies, 30 l of protein A-conjugated Sepharose beads were added to samples and rotated at 4°C for 1 h. The beads were collected by centrifugation at 3,000 rpm for 1 min and were then washed with 1 ml of PAN buffer (10 mM PIPES, pH 7, 20 g/ml aprotinin, 100 mM NaCl) containing 0.5% Nonidet P-40 followed by a wash with 1 ml of PAN buffer without Nonidet P-40. Samples were boiled for 10 min in 20 l of 2ϫ Laemmli buffer for Western blot analysis as described above.
Reverse Transcriptase-PCR-Total RNA was isolated using TRIzol reagent according to the manufacturer's instruction (Invitrogen, Carlsbad, CA). cDNA was synthesized with Moloney murine leukemia virus reverse transcriptase (Invitrogen) at 37°C for 1.5 h from 1 g of total RNA in 35 l of reaction buffer. A fraction (3 l) of cDNA was used for the 25-l PCR with recombinant Taq polymerase (Takara Bio Inc., Madison, WI). Glyceraldehyde-3-phosphate dehydrogenase was used as reference gene. The PCR primer pair of c-fos cDNA are 5Ј-CCTCGAG-GGGTTCCCGTAGA-3Ј and 5Ј-ACAGTACGTGGATATAGCGA-3Ј for 32 cycle amplifications at 94°C, 30 s; 58°C, 30 s; and 72°C, 30 s. For amplification of glyceraldehyde-3-phosphate dehydrogenase, the primer pair of 5Ј-AGACAGCCGCATCTTCTTGT-3Ј and 5Ј-CCACAGT-CTTCTGAGTGGCA-3Ј were used for 28 cycles using a condition described above. PCR products were detected by ethidium bromide staining after 1% agarose gel electrophoresis.
Phosphatase Treatment-Cells were harvested in 200 l of NEB lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM Na 4 P 2 O 7 , 1 mM ␤-glycerol phosphate, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, 10 mM N-ethylmaleimide), and the protein concentration was quantified by the Bradford method. Type 2 serine/threonine phosphatase A (PP2A, Upstate, Lake Placid, NY) or B (PP2B, Calbiochem, La Jolla, CA) was added to cell lysates to 0.0125 or 0.15 units/g of protein of cell lysates, respectively. For treatment of immunoprecipitated c-Fos, PP2A was added to the concentration equivalent to 0.0125 unit/g of protein of cell lysate. Sample volume was adjusted to 50 l with the phosphatase reaction buffer (20 mM MOPS, pH 7.5, 150 mM NaCl, 60 mM 2-mercaptoethanol, 1 mM MgCl 2 , 1 mM DTT, 10% glycerol, 2 mM EGTA, 0.1 mM MnCl 2 ) and incubated at 30°C for 30 min. For treatment with MG132, the 26 S proteasomal inhibitor was added to a final concentration of 50 M before PP2A treatment. Following the PP2A or PP2B reactions, Laemmli buffer was added for 10 min of boiling and Western blot analysis.
Calcineurin (PP2B) Activity Measurement-PP2B activity was measured using a commercially available kit (AK-816, BIOMOL, Plymouth Meeting, PA). The peptidyl phosphoserine phosphatase activity was measured using phosphoserine RII peptide as a substrate following the time course of appearance of inorganic phosphate detectable by malachite green (36) . Cardiomyocytes (3 ϫ 10 6 cells) were harvested in 250 l of lysis buffer (100 mM Tris, pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.2% Nonidet P-40, with freshly added KI-132 protease inhibitor mixture; BIOMOL). After the removal of free phosphate and nucleotides using a resin column, 5 l of cell lysates were incubated at 30°C for 30 min with the substrate RII peptide (75 M) in 50 l of reaction buffer (100 mM Tris, pH 7.5, 200 mM NaCl, 12 mM MgCl 2 , 1 mM DTT, 0.05% Nonidet P-40, 1 mM CaCl 2 ) in the presence or absence of the calcium chelator EGTA (20 mM). Products were measured by addition of 100 l of malachite green reagent for absorbance at 630 nm. The amount of phosphate produced was calculated using a linear standard curve generated from 0 to 2 nM inorganic phosphate. Total phosphate activity reflects the amount of inorganic phosphate generated without EGTA in the reaction buffer. The activity of PP2B was calculated as the difference between the amounts of phosphate produced in the absence versus presence of EGTA.
RESULTS
Hydrogen Peroxide Induces c-Fos Phosphorylation-H 2 O 2 activates the AP-1 transcription factor in cardiomyocytes (31) . Electrophoretic mobility shift assay indicates the presence of c-Fos protein in the AP-1 complex of H 2 O 2 -treated cardiomyocytes (Fig. 1 ). An increase in c-fos gene transcription has been shown to contribute to AP-1 activation in a number of experimental systems. As expected, an increase of c-Fos protein was observed in cardiomyocytes within 1 h after a 10-min exposure to 100 M H 2 O 2 (Fig. 2) . This increase reached the highest level at 2 h, and returned toward the basal level after 3 h (Fig. 2) . Addition of the protein synthesis inhibitor cycloheximide (2 g/ml) after H 2 O 2 treatment abolished the increase of c-Fos protein (Fig. 2) , indicating that new protein synthesis contributes to c-Fos elevation. Better separation with a higher percentage of SDS-PAGE yielded multiple bands of c-Fos (Fig. 3) . Time course and dose-response studies indicate the appearance of high molecular weight c-Fos bands at any given time point or with any H 2 O 2 dose when an increase in c-Fos protein was detectable (Fig. 3, A and B) . These data suggest the possibility of post-translational modification of newly synthesized c-Fos protein in H 2 O 2 -treated cardiomyocytes.
A few studies have indicated that c-Fos protein can be phosphorylated by serum stimulation (37) (38) (39) . We tested whether the higher molecular weight bands represented phosphorylated c-Fos protein by a dephosphorylation reaction using the PP2A. Cell lysates were harvested at 1 or 2 h after H 2 O 2 treatment for isolation of c-Fos by immunoprecipitation. Immunoprecipitated c-Fos was incubated with or without PP2A for 30 min at 30°C before detection by Western blot analysis. Immunoprecipitated c-Fos from H 2 O 2 -treated cells showed the presence of an upper band (Fig. 4) . Following incubation with PP2A, the upper band disappeared; indicating that c-Fos was phosphorylated in H 2 O 2 -treated cells (Fig. 4) .
The rat c-Fos protein contains 380 amino acids, among which 85 are serine, threonine, or tyrosine (40) . Antibodies against phosphorylated serine, threonine, or tyrosine were used to identify the type of phosphorylation of c-Fos protein after ( Fig. 5) . In contrast, phosphothreonine was not altered in H 2 O 2 -treated cells (Fig. 5) . No signal was detected with antiphosphotyrosine antibody.
H 2 O 2 has been shown to activate the PI3K, p70 S6 kinase, p42/44 ERK , p38, JNKs, and protein kinase C signaling pathways (30, 31, 41) . Pharmacological inhibitors allow us to test which of these signaling pathways might be involved in c-Fos phosphorylation. Cells were pretreated with specific inhibitors against ERKs (PD98059, 50 M), p38 (SB202190, 10 M), JNKs (JNK inhibitor I, 6 M), PI3K (LY294002, 20 M; and wortmannin, 100 nM), p70 S6 kinase (rapamycin, 10 ng/ml), protein kinase C (H-7, 2 M), protein kinase A (H-89, 10 M), or proteintyrosine kinase (genistein, 40 g/ml). The inhibitors at these doses have been reported to inhibit their targets in the literature or in our experimental model (30, 31) . After 30 min pretreatment with the inhibitors, cardiomyocytes were treated with H 2 O 2 for 10 min and were incubated for 2 h before harvesting for Western blot analyses. The inhibitors of p42/44 ERK , p38, PI3K, p70 S6 kinase, protein kinase C, protein kinase A, and tyrosine kinase did not appear to affect the formation of multiple bands of c-Fos in H 2 O 2 -treated cells (Fig. 6 , A and C-E). In contrast, JNK inhibitor I, a cell permeable 32-amino acid peptide derived from the C-terminal domain of a JNKbinding protein and inhibits JNK activity by preventing JNK phosphorylation, caused a decreased c-Fos phosphorylation and protein level (Fig. 6B) .
JNKs are known to phosphorylate c-Jun and cause immediate activation of AP-1 transcription factor. The c-fos gene contains AP-1 binding sites in the promoter region, whereas oxidants have been shown to induce the transcription of the c-fos gene (32, 33, 42) . To exclude the possibility that inhibiting JNKs prevents c-fos transcription, we measured the level of c-fos transcripts after H 2 O 2 treatment in the presence of the JNK inhibitor I. The time course studies showed that an increase of c-fos transcripts occurred at 30 min to 1 h after H 2 O 2 treatment (Fig. 7A) . Treatment of the JNK inhibitor I did not affect the increase of c-fos transcripts (Fig. 7B) . These data support that the observed effect of JNK inhibitor I on the c-Fos protein, as shown in Fig. 6B , is related to post-translational modification, not c-fos transcription.
Phosphorylation Protects c-Fos Protein from Degradation-JNK inhibitor I inhibited c-Fos phosphorylation and c-Fos protein accumulation, suggesting the possibility that unphosphorylated c-Fos protein is rapidly degraded. The time course studies seemed to indicate that the lower molecular weight bands of c-Fos disappeared first (Fig. 8A) . To determine whether the proteosome plays a role in degradation of c-Fos protein, we tested the effect of selective inhibitors of 26 S proteasome, MG132, and Proteasomal Inhibitor I (43, 44), on the level of c-Fos protein following H 2 O 2 treatment. Leupeptin, an inhibitor of cysteine protease and trypsin-like protease, was also tested for the potential effect of cytosolic proteases on c-Fos protein degradation. c-Fos protein levels declined 3 h after H 2 O 2 treatment from its peak increase at 2 h (Fig. 8, B and C) . MG132 and proteasomal inhibitor I, but not leupeptin, prevented the decline of c-Fos protein at 3 and 4 h after H 2 O 2 treatment (Fig. 8, B and C) . Consistent with the time course studies, the proteasomal inhibitors were able to retain the lower molecular weight band of c-Fos (Fig. 8B) , suggesting that unphosphorylated c-Fos is the target of proteosomal degradation.
Because proteasomal degradation requires its target to be (Fig. 9) .
When we were testing for c-Fos phosphorylation by treating the whole cell lysate with PP2A in test tubes, c-Fos protein disappeared (Fig. 10A) . Because the lysis buffer contains the inhibitors of cytosolic and lysosomal proteases, i.e. leupeptin, aproptinin, and phenylmethylsulfonyl fluoride, this finding suggests that c-Fos is degraded by the proteasomes once dephosphorylated. To demonstrate this, MG132 was added to the whole cell lysate during the dephosphorylation reaction in test tubes using PP2A. The results showed that addition of MG132 to the cell lysate during PP2A treatment inhibited the loss of c-Fos protein from H 2 O 2 -treated cardiomyocytes (Fig. 10A) .
Recent evidence has indicated a role of calcineurin (i.e. PP2B) in cardiomyocyte hypertrophy (19, 47) . PP2B is activated in a calcium-and calmodulin-dependent manner (48) . H 2 O 2 activates PI3K (30), a lipid kinase that adds a phosphate group to the free 3-position of the inositol ring of phosphatidylinositol or phosphoinositides. The products of PI3K participate in multiple signaling events (49) . One of the products, phosphatidylinositol 3,4,5-P 3 activates phospholipase C␥, which releases inositol 1,4,5-triphosphate from the lipids. Inositol 1,4,5-triphosphate triggers an increase in cytosolic Ca 2ϩ . These lines of evidence suggest that H 2 O 2 treatment may lead to activation of PP2B. We therefore tested the effect of PP2B on levels of c-Fos protein in vitro by comparing to PP2A. Unlike PP2A, although PP2B caused a minor shift in the molecular weight of c-Fos protein, the catalytic reaction with PP2B did not cause degradation of the c-Fos protein in vitro (Fig. 10B) .
We measured the activities of phosphatases and PP2B using phosphoserine RII peptide as a substrate with cardiomyocyte cell lysates collected at 2-4 h after H 2 O 2 treatment. The assay showed an increase in total phosphatase activity 2 h after H 2 O 2 treatment and the activity remained throughout the time points tested (Fig. 11A) . In contrast, the activity of EGTA-sensitive phosphatase, presumably PP2B, peaked at 2 h (Fig. 11A) . Using this assay, we have tested the effect of cypermethrin (CY), a specific inhibitor of PP2B (50) , and okadaic acid (OA), a general phosphatase inhibitor (51) . The results showed that CY prevented H 2 O 2 from activating PP2B, whereas OA reduced the overall activity of phosphatases (Fig. 11B) .
The time course studies and in vitro dephosphorylation experiments suggest that phosphorylation protects c-Fos from being degraded by the proteasome in H 2 O 2 -treated cells. To A and B) . The immunoprecipitates were used for SDS-PAGE (7% gel) and Western blot analyses with mouse monoclonal antibodies against ubiquitin (A). The same membrane was stripped and blotted with rabbit polyclonal antibodies against c-Fos (B). Alternatively, cell lysates containing 500 g of protein were used for immunoprecipitation of ubiquitin and the immunoprecipitates were separated using SDS-PAGE (7% gel) for Western blot analysis using antibodies against c-Fos (C). IB, immunoblotted.
FIG. 10.
Disappearance of c-Fos protein during treatment of cell lysates with PP2A. Cardiomyocytes were treated with 100 M H 2 O 2 for 10 min and harvested 1 (A) or 2 h (A and B) later in a buffer containing protease inhibitors (1 M phenylmethylsulfonyl fluoride, 100 g/ml leupeptin, and 10 g/ml aproptinin). Cell lysates containing 20 g of proteins were incubated with or without PP2A (0.0125 unit/g of protein) or PP2B (0.15 unit/g of protein) for 30 min. MG132 (50 M) was added to corresponding samples before the phosphatase reaction. c-Fos protein was detected using SDS-PAGE (7% gel) and Western blot analyses. determine whether this scenario applies to in vivo situations, we determined whether we could extend the time course of c-Fos elevation with OA or CY in H 2 O 2 -treated cardiomyocytes. The results show that OA, but not CY, extended the time course of c-Fos elevation (Fig. 12) . This article has described a role of post-translational modification in regulating the stability of c-Fos protein in H 2 O 2 -treated cardiomyocytes. H 2 O 2 has been shown to induce cardiomyocyte hypertrophy (15) . Although the discovery of H 2 O 2 inducing hypertrophy is relatively new and demands further mechanistic studies, serum, phenylephrine, AngII, and endothelin-1 are well known inducers of cardiomyocyte hypertrophy. We have tested whether post-translational modification of c-Fos is a general phenomenon with all hypertrophy inducers and found that it appeared to be the case (Fig. 13) . This suggests the importance of including the consideration of protein stabilization in AP-1 activation, transcriptional regulation, and hypertrophy mechanisms.
c-Fos protein is metabolically unstable and can be degraded rapidly with a half-life in the range of 1 h in tumor cells (52) . This feature is important for quick turn-off of AP-1 activity and entitles the transcription factor to a tight control mechanism. Multiple proteolytic machineries are thought to play a part in c-Fos protein degradation, including calpains, lysosomal proteases, and the proteasome (53-56). Stancovski et al. (57) have demonstrated that c-Fos is conjugated with ubiquitin and is degraded by the 26 S proteasome in vitro and in Chinese hamster ovary cells. Mutant Chinese hamster ovary cells that lack the ubiquitin activating enzyme (E1) cannot ubiquitinate c-Fos and have increased c-Fos stability (57) . Based on protein sequence information, c-Fos contains 14 lysine residues, each of which in theory can possibly form a covalent linkage with the Gly-Gly tail of ubiquitin (45, 46) . Ubiquitination is a key step in proteasomal degradation of c-Fos protein. The discovery of ubiquitin conjugation on c-Fos protein and the inhibitory effect of proteosomal inhibitors on the decay of c-Fos protein in our study suggest the importance of proteasome-mediated degradation of c-Fos protein in H 2 O 2 -treated cardiomyocytes.
Phosphorylation of c-Fos protein can occur in the COOH terminus with serum stimulation (37) (38) (39) RSK exposes a docking site for ERKs, resulting in further phosphorylation of c-Fos (37) . Changing serines 362 and 374 to alanines to eliminate phosphorylation resulted in a reduced half-life of the mutant c-Fos proteins. In contrast, mutating serines 362 and 374 to aspartic acids to mimic phosphorylation caused an increase in c-Fos stability and enhanced AP-1 transactivation activity (38) . In our experimental system, MEK inhibitor PD98059 has been shown to prohibit oxidants from activating ERKs (31) . Failure of PD98059 in inhibiting c-Fos phosphorylation indicates a novel mechanism of c-Fos phosphorylation independant of ERKs, and therefore perhaps unique to oxidative stress.
Our data collectively suggest that JNKs serve as an upstream kinase phosphorylating c-Fos in H 2 O 2 -treated cardiomyocytes. JNKs have been shown to phosphorylate serines 63 and 73 in the NH 2 -terminal activation domain of c-Jun, leading to reduced protease degradation of c-Jun protein involving the 26 S proteasome (58) . JNKs preferentially phosphorylate serine in front of proline in the substrate proteins (59). We have found that H 2 O 2 induces serine phosphorylation of c-Fos. Protein sequence information reveals that c-Fos protein has six serine residues that fit with the requirement of JNK substrates: serine 21, 32, 42, 70, 133, or 374. Only one of these serine residues is located in the COOH-terminal region. A study using COOH terminus-deleted c-Fos demonstrated increased degradation of c-Fos protein in vitro, suggesting that phosphorylation of c-Fos protein at the COOH-terminal might be responsible for increased c-Fos stability (38) . If this is indeed the case, serine 374 of c-Fos appears to be a most likely target of H 2 O 2 -induced phosphorylation.
We have tested the possibility that PP2B mediates dephosphorylation and therefore degradation of c-Fos protein. However, the in vitro phosphatase reaction shows that PP2A, but not PP2B, caused c-Fos degradation. Although cyclosporin A is a commonly used inhibitor of PP2B, this compound also inhibits mitochondrial membrane permeability transition, an event known to be induced by oxidative stress (60 -62) . Additionally, evidence points to the fact that cyclosporin A in cellular systems may cause increased generation of oxidants (63) . To avoid these complications, we have used CY to inhibit PP2B (50) . Although CY inhibited the activity of PP2B, it failed to extend the time course of c-Fos elevation, indicating that PP2B may not participate in dephosphorylation of c-Fos in vivo. These findings are consistent with the characteristics of this enzyme, which has a narrowed range of substrates and often requires a close contact with its substrate for dephosphorylation (64) . Nevertheless, our data suggest that OA-sensitive phosphatases are a central player in dephosphorylating c-Fos. To date, there are about 40 genes encoding serine/threonine phosphatases that can be divided into two distinct families based on the amino acid sequence homologies of catalytic subunits: phosphoprotein phosphatase and magnesium or metal-dependent protein phosphatase (51, 65) . Phosphoprotein phosphatase is a large family and most members in this family, for example, PP1, PP2A, PP3, and PP4, are sensitive to an inhibitory effect of OA at a nanomolar dose range (51) . PP1 and PP2A are more abundant and have been better studied than other phosphatases. These two phosphatases contain multiple regulatory subunits and have been shown to regulate a variety of cellular functions (66) . Which phosphatase participates in dephosphorylation and regulation of the stability of c-Fos protein in H 2 O 2 -treated cardiomyocytes remains to be elucidated.
